PVIVAX

Knowledge sharing for relapsing malaria

PVIVAX Knowledge sharing for relapsing malaria

Search

  • P. vivax malaria
    • Malaria and P. vivax malaria
    • Symptoms & severity
    • Illness and mortality
    • Populations at risk
      • Pregnant women and children
      • Migratory populations
    • Role in malaria elimination
    • Lifecycle
    • Relapses
    • Vectors
  • Diagnosis & treatment
    • Diagnostic methods
      • Microscopy
      • Rapid diagnostic tests
      • Molecular methods & serology
    • Diagnosing severe vivax malaria
    • Treatment
      • Radical cure
      • Blood stage treatment
      • Liver stage treatment
    • G6PD Deficiency
      • G6PD Global Prevalence
      • G6PD diagnostics
      • Types of G6PD clinical diagnostic tests
  • Regions & countries
    • Africa
    • Eastern Mediterranean
    • South East Asia
    • The Americas
    • Western Pacific
  • In the field
    • Projects
      • The Partnership for Vivax Elimination (PAVE)
    • Stories and Videos
  • Tools
    • Study database
  • Resources
  • News & events
    • Past events
  • About us
HomeNews & events

News

1

Photo: Damien Schumann/MMV

Two positive phase III studies of tafenoquine for the radical cure of Plasmodium vivax malaria

16 Jan 2019
Photo: Fundação de Medicina Tropical

Single-dose tafenoquine for radical cure of P. vivax malaria submitted for regulatory approval in Brazil

21 Sep 2018
Photo: BMC St Jude

Kozenis (tafenoquine) approved by the Australian Therapeutic Goods Administration for the radical cure of P. vivax malaria

21 Sep 2018
Photo: Maud Lugand/MMV

US FDA approves Krintafel (tafenoquine) for the radical cure of P. vivax malaria

20 Jul 2018

US FDA Advisory Committee endorses the effectiveness and safety of single-dose tafenoquine for the radical cure of P. vivax malaria

12 Jul 2018

Pages

  • « first
  • ‹ previous
  • 1
  • 2
  • 3
  • 4
1

Events

Disclaimer

Disclaimer: MMV accepts no liability for the information presented here or for the consequences of any actions taken on the basis of this information. 

Subscribe to our newsletter

Get in touch

Contact us.

Submit information

Subscribe

Join the mailing list

Follow us

  • Twitter
  • LinkedIn
  • Facebook
  • Disclaimer
  • Privacy policy
A Remora website by Manta Ray Media